The pharmacogenetic background of hepatitis C treatment

Mutation Research - Reviews in Mutation Research

Volumn 751, Issue 1, 2012, Pages 36-48

  Schlecker, Christina ^a   Ultsch, Alfred ^b   Geisslinger, Gerd ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Data mining; Gene Ontology; Genetics; Hepatitis C; Informatics; Knowledge generation; Pharmacogenetics; Target identification

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOCHROME P450; INOSINE TRIPHOSPHATE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 28B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MANNAN BINDING LECTIN; NUCLEOSIDE TRANSPORTER; PHOSPHOPROTEIN; RIBAVIRIN; SEROTONIN; TELAPREVIR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

CYTOTOXIC T LYMPHOCYTE; DOWNSTREAM PROCESSING; GENETIC CODE; GENETIC VARIABILITY; HEMOCHROMATOSIS; HEPATITIS C; HISTOCOMPATIBILITY COMPLEX; HUMAN; MACHINE LEARNING; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VIRAL CLEARANCE;

HEPATITIS C VIRUS;

EID: 84862187156     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2012.02.001     Document Type: Review

References (167)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345:41-52.
2. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
3. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002, 36:S3-S20.
4. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339:1485-1492.
5. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
6. Munir S., Saleem S., Idrees M., Tariq A., Butt S., Rauff B., Hussain A., Badar S., Naudhani M., Fatima Z., Ali M., Ali L., Akram M., Aftab M., Khubaib B., Awan Z. Hepatitis C treatment: current and future perspectives. Virol. J. 2010, 7:296.
7. Lemon S.M., McKeating J.A., Pietschmann T., Frick D.N., Glenn J.S., Tellinghuisen T.L., Symons J., Furman P.A. Development of novel therapies for hepatitis C. Antiviral Res. 2010, 86:79-92.
8. Akuta N., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Chayama K., Nakamura Y., Kumada H. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52:421-429.
9. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., Harris M.A., Hill D.P., Issel-Tarver L., Kasarskis A., Lewis S., Matese J.C., Richardson J.E., Ringwald M., Rubin G.M., Sherlock G. Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25:25-29.
10. Hu P., Bader G., Wigle D.A., Emili A. Computational prediction of cancer-gene function. Nat. Rev. Cancer 2007, 7:23-34.
11. Iorio F., Bosotti R., Scacheri E., Belcastro V., Mithbaokar P., Ferriero R., Murino L., Tagliaferri R., Brunetti-Pierri N., Isacchi A., di Bernardo D. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14621-14626.
12. Sirota M., Dudley J.T., Kim J., Chiang A.P., Morgan A.A., Sweet-Cordero A., Sage J., Butte A.J. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 2011, 3:96ra77.
13. Chiang A.P., Butte A.J. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin. Pharmacol. Ther. 2009, 86:507-510.
14. White V.J. A statistical approach to designing search filters to find systematic reviews: objectivity enhances accuracy. J. Informat. Sci. 2001, 27:357-370.
15. Doehring A., Hofmann W.P., Schlecker C., Zeuzem S., Sarrazin C., Berg T., Muller T., Herrmann E., Geisslinger G., Lötsch J. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenet. Genomics 2011, 21:289-296.
16. Afdhal N.H., McHutchison J.G., Zeuzem S., Mangia A., Pawlotsky J.M., Murray J.S., Shianna K.V., Tanaka Y., Thomas D.L., Booth D.R., Goldstein D.B., Hepatitis C pharmacogenetics: state of the art in 2010 Hepatology 2011, 53:336-345.
17. Dring M.M., Morrison M.H., McSharry B.P., Guinan K.J., Hagan R., O'Farrelly C., Gardiner C.M. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5736-5741.
18. Chen J.Y., Lin C.Y., Wang C.M., Lin Y.T., Kuo S.N., Shiu C.F., Chang S.W., Wu J., Sheen I.S. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011, 12:300-309.
19. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R., Poordad F., Lawitz E.J., McCone J., Shiffman M.L., Galler G.W., Lee W.M., Reindollar R., King J.W., Kwo P.Y., Ghalib R.H., Freilich B., Nyberg L.M., Zeuzem S., Poynard T., Vock D.M., Pieper K.S., Patel K., Tillmann H.L., Noviello S., Koury K., Pedicone L.D., Brass C.A., Albrecht J.K., Goldstein D.B., McHutchison J.G. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129. e118.
20. Ito K., Higami K., Masaki N., Sugiyama M., Mukaide M., Saito H., Aoki Y., Sato Y., Imamura M., Murata K., Nomura H., Hige S., Adachi H., Hino K., Yatsuhashi H., Orito E., Kani S., Tanaka Y., Mizokami M. The rs8099917 polymorphism when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J. Clin. Microbiol. 2011, 49:1853-1860.
21. Tate S.K., Goldstein D.B. Will tomorrow's medicines work for everyone?. Nat. Genet. 2004, 36:S34-S42.
22. Azakami T., Hayes C.N., Sezaki H., Kobayashi M., Akuta N., Suzuki F., Kumada H., Abe H., Miki D., Tsuge M., Imamura M., Kawakami Y., Takahashi S., Ochi H., Nakamura Y., Kamatani N., Chayama K. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J. Med. Virol. 2011, 83:1048-1057.
23. Ochi H., Maekawa T., Abe H., Hayashida Y., Nakano R., Kubo M., Tsunoda T., Hayes C.N., Kumada H., Nakamura Y., Chayama K. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010, 139:1190-1197.
24. Sakamoto N., Tanaka Y., Nakagawa M., Yatsuhashi H., Nishiguchi S., Enomoto N., Azuma S., Nishimura-Sakurai Y., Kakinuma S., Nishida N., Tokunaga K., Honda M., Ito K., Mizokami M., Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol. Res. 2010, 40:1063-1071.
25. Suzuki F., Suzuki Y., Akuta N., Sezaki H., Hirakawa M., Kawamura Y., Hosaka T., Kobayashi M., Saito S., Arase Y., Ikeda K., Chayama K., Kamatani N., Nakamura Y., Miyakawa Y., Kumada H. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011, 53:415-421.
26. Camon E., Magrane M., Barrell D., Binns D., Fleischmann W., Kersey P., Mulder N., Oinn T., Maslen J., Cox A., Apweiler R. The Gene Ontology Annotation (GOA) project: implementation of GO in SWISS-PROT, TrEMBL, and InterPro. Genome Res. 2003, 13:662-672.
27. Camon E., Magrane M., Barrell D., Lee V., Dimmer E., Maslen J., Binns D., Harte N., Lopez R., Apweiler R. The Gene Ontology Annotation (GOA) database: sharing knowledge in Uniprot with Gene Ontology. Nucleic Acids Res. 2004, 32:D262-D266.
28. Backes C., Keller A., Kuentzer J., Kneissl B., Comtesse N., Elnakady Y.A., Muller R., Meese E., Lenhof H.P. GeneTrail - advanced gene set enrichment analysis. Nucleic Acids Res. 2007, 35:W186-W192.
29. Gatti D.M., Barry W.T., Nobel A.B., Rusyn I., Wright F.A. Heading down the wrong pathway: on the influence of correlation within gene sets. BMC Genomics 2010, 11:574.
30. Alric L., Fort M., Izopet J., Vinel J.P., Charlet J.P., Selves J., Puel J., Pascal J.P., Duffaut M., Abbal M. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997, 113:1675-1681.
31. Martinetti M., Pacati I., Cuccia M., Badulli C., Pasi A., Salvaneschi L., Minola E., De Silvestri A., Iannone A.M., Maccabruni A. Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int. J. Immunopathol. Pharmacol. 2006, 19:369-378.
32. Cordero E.A., Veit T.D., da Silva M.A., Jacques S.M., Silla L.M., Chies J.A. HLA-G polymorphism influences the susceptibility to HCV infection in sickle cell disease patients. Tissue Antigens 2009, 74:308-313.
33. Bevilacqua E., Fabris A., Floreano P., Pembrey L., Newell M.L., Tovo P.A., Amoroso A. Genetic factors in mother-to-child transmission of HCV infection. Virology 2009, 390:64-70.
34. Almarri A., El Dwick N., Al Kabi S., Sleem K., Rashed A., Ritter M.A., Batchelor J.R. Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum. Immunol. 1998, 59:239-242.
35. Sim H., Wojcik J., Margulies M., Wade J.A., Heathcote J. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J. Viral Hepat. 1998, 5:249-253.
36. Yu M.L., Dai C.Y., Chen S.C., Chiu C.C., Lee L.P., Lin Z.Y., Hsieh M.Y., Wang L.Y., Chuang W.L., Chang W.Y. Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection. J. Infect. Dis. 2003, 188:62-65.
37. Miyaguchi S., Saito H., Ebinuma H., Morizane T., Ishii H. Possible association between HLA antigens and the response to interferon in Japanese patients with chronic hepatitis C. Tissue Antigens 1997, 49:605-611.
38. Kikuchi I., Ueda A., Mihara K., Miyanaga O., Machidori H., Ishikawa E., Tamura K. The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 1998, 10:859-863.
39. Tseng K.C., Chang C.K., Chou A.L., Hsieh Y.H., Tseng C.A., Lai N.S. Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in Taiwan. Hepatogastroenterology 2010, 57:456-461.
40. Romero-Gomez M., Gonzalez-Escribano M.F., Torres B., Barroso N., Montes-Cano M.A., Sanchez-Munoz D., Nunez-Roldan A., Aguilar-Reina J. HLA class I B44 is associated with sustained response to interferon+ribavirin therapy in patients with chronic hepatitis C. Am. J. Gastroenterol. 2003, 98:1621-1626.
41. Ali L., Mansoor A., Ahmad N., Siddiqi S., Mazhar K., Muazzam A.G., Qamar R., Khan K.M. Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J. Gen. Virol. 2010, 91:1931-1938.
42. Airoldi A., Zavaglia C., Silini E., Tinelli C., Martinetti M., Asti M., Rossini A., Vangeli M., Salvaneschi L., Pinzello G. Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C. Eur. J. Immunogenet. 2004, 31:259-265.
43. Thursz M., Yallop R., Goldin R., Trepo C., Thomas H.C. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999, 354:2119-2124.
44. Knolle P.A., Kremp S., Hohler T., Krummenauer F., Schirmacher P., Gerken G. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J. Viral Hepat. 1998, 5:399-406.
45. Bonkovsky H.L., Naishadham D., Lambrecht R.W., Chung R.T., Hoefs J.C., Nash S.R., Rogers T.E., Banner B.F., Sterling R.K., Donovan J.A., Fontana R.J., Di Bisceglie A.M., Ghany M.G., Morishima C. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006, 131:1440-1451.
46. Bonkovsky H.L., Banner B.F., Rothman A.L. Iron and chronic viral hepatitis. Hepatology 1997, 25:759-768.
47. Lebray P., Zylberberg H., Hue S., Poulet B., Carnot F., Martin S., Chretien Y., Pol S., Caillat-Zuckman S., Brechot C., Nalpas B. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J. Viral Hepat. 2004, 11:175-182.
48. Yee L.J., Perez K.A., Tang J., van Leeuwen D.J., Kaslow R.A. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J. Infect. Dis. 2003, 187:1264-1271.
49. Cullen S.P., Martin S.J. Mechanisms of granule-dependent killing. Cell Death Differ. 2008, 15:251-262.
50. Maurer M., Loserth S., Kolb-Maurer A., Ponath A., Wiese S., Kruse N., Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002, 54:1-8.
51. Wang X.B., Zhao X., Giscombe R., Lefvert A.K. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun. 2002, 3:233-234.
52. Tilg H., Kaser A., Moschen A.R. How to modulate inflammatory cytokines in liver diseases. Liver Int. 2006, 26:1029-1039.
53. Dai C.Y., Chuang W.L., Chang W.Y., Chen S.C., Lee L.P., Hsieh M.Y., Hou N.J., Lin Z.Y., Huang J.F., Wang L.Y., Yu M.L. Tumor necrosis factor-alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J. Infect. Dis. 2006, 193:98-101.
54. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3195-3199.
55. Sabat R., Grutz G., Warszawska K., Kirsch S., Witte E., Wolk K., Geginat J. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010, 21:331-344.
56. Payvandi F., Amrute S., Fitzgerald-Bocarsly P. Exogenous and endogenous IL-10 regulate IFN-alpha production by peripheral blood mononuclear cells in response to viral stimulation. J. Immunol. 1998, 160:5861-5868.
57. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996, 24:6-9.
58. Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 1999, 30:376-382.
59. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., Powell E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
60. Morgan T.R., Lambrecht R.W., Bonkovsky H.L., Chung R.T., Naishadham D., Sterling R.K., Fontana R.J., Lee W.M., Ghany M.G., Wright E.C., O'Brien T.R. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J. Hepatol. 2008, 49:548-556.
61. Yee L.J., Tang J., Gibson A.W., Kimberly R., Van Leeuwen D.J., Kaslow R.A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001, 33:708-712.
62. Knapp S., Hennig B.J., Frodsham A.J., Zhang L., Hellier S., Wright M., Goldin R., Hill A.V., Thomas H.C., Thursz M.R. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55:362-369.
63. Chuang J.Y., Yang S.S., Lu Y.T., Hsieh Y.Y., Chen C.Y., Chang S.C., Chang C.S., Yeh H.Z., Kao J.H. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig. Liver Dis. 2009, 41:424-430.
64. Constantini P.K., Wawrzynowicz-Syczewska M., Clare M., Boron-Kaczmarska A., McFarlane I.G., Cramp M.E., Donaldson P.T. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002, 22:404-412.
65. Vidigal P.G., Germer J.J., Zein N.N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J. Hepatol. 2002, 36:271-277.
66. Hsu K.C., Chida S., Geraghty D.E., Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol. Rev. 2002, 190:40-52.
67. Middleton D., Curran M., Maxwell L. Natural killer cells and their receptors. Transpl. Immunol. 2002, 10:147-164.
68. Gonzalez V.D., Landay A.L., Sandberg J.K. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin. Immunol. 2010, 135:12-25.
69. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., Cheng J., Goedert J.J., Vlahov D., Hilgartner M., Cox S., Little A.M., Alexander G.J., Cramp M.E., O'Brien S.J., Rosenberg W.M., Thomas D.L., Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-874.
70. Estefania E., Flores R., Gomez-Lozano N., Aguilar H., Lopez-Botet M., Vilches C. Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J. Immunol. 2007, 178:4402-4410.
71. Carneiro V.L., Lemaire D.C., Bendicho M.T., Souza S.L., Cavalcante L.N., Angelo A.L., Freire S.M., Mendes C.M., Santana N., Lyra L.G., Lyra A.C. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int. 2010, 30:567-573.
72. Vidal-Castineira J.R., Lopez-Vazquez A., Diaz-Pena R., Alonso-Arias R., Martinez-Borra J., Perez R., Fernandez-Suarez J., Melon S., Prieto J., Rodrigo L., Lopez-Larrea C. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J. Virol. 2010, 84:475-481.
73. Ahlenstiel G., Berg T., Woitas R.P., Grunhage F., Iwan A., Hess L., Brackmann H.H., Kupfer B., Schernick A., Sauerbruch T., Spengler U. Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. J. Hepatol. 2003, 39:245-252.
74. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
75. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
76. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
77. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
78. Horsmans Y., Berg T., Desager J.P., Mueller T., Schott E., Fletcher S.P., Steffy K.R., Bauman L.A., Kerr B.M., Averett D.R. Isatoribine an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42:724-731.
79. Schott E., Witt H., Neumann K., Bergk A., Halangk J., Weich V., Muller T., Puhl G., Wiedenmann B., Berg T. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J. Viral Hepat. 2008, 15:71-78.
80. Bissell D.M., Roulot D., George J. Transforming growth factor beta and the liver. Hepatology 2001, 34:859-867.
81. Tsushima H., Kawata S., Tamura S., Ito N., Shirai Y., Kiso S., Doi Y., Yamada A., Oshikawa O., Matsuzawa Y. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J. Hepatol. 1999, 30:1-7.
82. Takahashi K., Ip W.E., Michelow I.C., Ezekowitz R.A. The mannose-binding lectin: a prototypic pattern recognition molecule. Curr. Opin. Immunol. 2006, 18:16-23.
83. Brown K.S., Ryder S.D., Irving W.L., Sim R.B., Hickling T.P. Mannan binding lectin and viral hepatitis. Immunol. Lett. 2007, 108:34-44.
84. Garred P., Larsen F., Seyfarth J., Fujita R., Madsen H.O. Mannose-binding lectin and its genetic variants. Genes Immun. 2006, 7:85-94.
85. Matsushita M., Hijikata M., Ohta Y., Mishiro S. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J. Hepatol. 1998, 29:695-700.
86. Matsushita M., Hijikata M., Ohta Y., Iwata K., Matsumoto M., Nakao K., Kanai K., Yoshida N., Baba K., Mishiro S., Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL. Arch. Virol. 1998, 143:645-651.
87. Alves Pedroso M.L., Boldt A.B., Pereira-Ferrari L., Steffensen R., Strauss E., Jensenius J.C., Ioshii S.O., Messias-Reason I. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin. Exp. Immunol. 2008, 152:258-264.
88. Lange C.M., Bojunga J., Ramos-Lopez E., von Wagner M., Hassler A., Vermehren J., Herrmann E., Badenhoop K., Zeuzem S., Sarrazin C. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J. Hepatol. 2011, 54:887-893.
89. Bucki R., Leszczynska K., Namiot A., Sokolowski W., Cathelicidin LL-37: a multitask antimicrobial peptide. Arch. Immunol. Ther. Exp. (Warsz) 2010, 58:15-25.
90. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
91. Wozniak M.A., Itzhaki R.F., Faragher E.B., James M.W., Ryder S.D., Irving W.L. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002, 36:456-463.
92. Mueller T., Gessner R., Sarrazin C., Graf C., Halangk J., Witt H., Kottgen E., Wiedenmann B., Berg T. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology 2003, 38:1592. author reply 1592-1593.
93. Eto M., Watanabe K., Chonan N., Ishii K. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 1988, 72:123-128.
94. Mihaila R., Nedelcu L., Fratila O., Rezi E.C., Domnariu C., Ciuca R., Zaharie A.V., Olteanu A., Bera L., Deac M. Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. Hepatogastroenterology 2009, 56:1704-1709.
95. Chung R.T., Gale M., Polyak S.J., Lemon S.M., Liang T.J., Hoofnagle J.H. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 2008, 47:306-320.
96. Platanias L.C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol. Ther. 2003, 98:129-142.
97. Ishida H., Ohkawa K., Hosui A., Hiramatsu N., Kanto T., Ueda K., Takehara T., Hayashi N. Involvement of p38 signaling pathway in interferon-alpha-mediated antiviral activity toward hepatitis C virus. Biochem. Biophys. Res. Commun. 2004, 321:722-727.
98. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 2010, 30:555-564.
99. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda) a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006, 80:4501-4509.
100. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., Bartenschlager R. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-703.
101. Huang Y., Yang H., Borg B.B., Su X., Rhodes S.L., Yang K., Tong X., Tang G., Howell C.D., Rosen H.R., Thio C.L., Thomas D.L., Alter H.J., Sapp R.K., Liang T.J. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:985-990.
102. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
103. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
104. Lange C.M., Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J. Hepatol. 2011, 55:692-701.
105. Chayama K., Hayes C.N., Hepatitis C virus: how genetic variability affects pathobiology of disease. J. Gastroenterol. Hepatol. 2011, 26(Suppl. 1):83-95.
106. Balagopal A., Thomas D.L., Thio C.L. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010, 139:1865-1876.
107. Ahlenstiel G., Booth D.R., George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J. Gastroenterol. 2010, 45:903-910.
108. Rauch A., Rohrbach J., Bochud P.Y. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur. J. Clin. Invest. 2010, 40:950-959.
109. Doehring A., Hofmann W.P., Schlecker C., Zeuzem S., Susser S., Geisslinger G., Sarrazin C., Lötsch J. Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir. Ther. 2010, 15:1099-1106.
110. Lange C.M., Moradpour D., Doehring A., Lehr H.A., Mullhaupt B., Bibert S., Bochud P.Y., Antonino A.T., Pascual M., Farnik H., Shi Y., Bechstein W.O., Moench C., Hansmann M.L., Sarrazin C., Lötsch J., Zeuzem S., Hofmann W.P. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J. Hepatol. 2011, 55:322-327.
111. Sarrazin C., Susser S., Doehring A., Lange C.M., Muller T., Schlecker C., Herrmann E., Lötsch J., Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 2011, 54:415-421.
112. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
113. Rauch A., Kutalik Z., Descombes P., Cai T., di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Gunthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic Hepatitis C and treatment failure - A Genome-Wide Association Study. Gastroenterology 2010, 138:1338-1345.
114. Welzel T.M., Morgan T.R., Bonkovsky H.L., Naishadham D., Pfeiffer R.M., Wright E.C., Hutchinson A.A., Crenshaw A.T., Bashirova A., Carrington M., Dotrang M., Sterling R.K., Lindsay K.L., Fontana R.J., Lee W.M., Di Bisceglie A.M., Ghany M.G., Gretch D.R., Chanock S.J., Chung R.T., O'Brien T.R. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009, 49:1847-1858.
115. Sleijfer S., Bannink M., Van Gool A.R., Kruit W.H., Stoter G. Side effects of interferon-alpha therapy. Pharm. World Sci. 2005, 27:423-431.
116. Wada M., Marusawa H., Yamada R., Nasu A., Osaki Y., Kudo M., Nabeshima M., Fukuda Y., Chiba T., Matsuda F. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. J. Viral Hepat. 2009, 16:388-396.
117. Seth R.B., Sun L., Chen Z.J. Antiviral innate immunity pathways. Cell Res. 2006, 16:141-147.
118. Yoshida K., Alagbe O., Wang X., Woolwine B., Thornbury M., Raison C.L., Miller A.H. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 2005, 52:55-61.
119. Fujimoto Y., Ochi H., Maekawa T., Abe H., Hayes C.N., Kumada H., Nakamura Y., Chayama K. A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. J. Hepatol. 2011, 54:629-639.
120. Tsukada H., Ochi H., Maekawa T., Abe H., Fujimoto Y., Tsuge M., Takahashi H., Kumada H., Kamatani N., Nakamura Y., Chayama K. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 2009, 136:1796-1805. e1796.
121. Marie I., Rebouillat D., Hovanessian A.G. The expression of both domains of the 69/71kDa 2',5' oligoadenylate synthetase generates a catalytically active enzyme and mediates an anti-viral response. Eur. J. Biochem. 1999, 262:155-165.
122. Rebouillat D., Hovanessian A.G. The human 2',5'-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J. Interferon Cytokine Res. 1999, 19:295-308.
123. Yakub I., Lillibridge K.M., Moran A., Gonzalez O.Y., Belmont J., Gibbs R.A., Tweardy D.J. Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J. Infect. Dis. 2005, 192:1741-1748.
124. Su X., Yee L.J., Im K., Rhodes S.L., Tang Y., Tong X., Howell C., Ramcharran D., Rosen H.R., Taylor M.W., Liang T.J., Yang H. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J. Hepatol. 2008, 49:184-191.
125. Clemens M.J. PKR - a protein kinase regulated by double-stranded RNA. Int. J. Biochem. Cell Biol. 1997, 29:945-949.
126. Knapp S., Yee L.J., Frodsham A.J., Hennig B.J., Hellier S., Zhang L., Wright M., Chiaramonte M., Graves M., Thomas H.C., Hill A.V., Thursz M.R. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003, 4:411-419.
127. Suzuki F., Arase Y., Suzuki Y., Tsubota A., Akuta N., Hosaka T., Someya T., Kobayashi M., Saitoh S., Ikeda K., Matsuda M., Takagi K., Satoh J., Kumada H. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepat. 2004, 11:271-276.
128. Hijikata M., Ohta Y., Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000, 43:124-127.
129. Hijikata M., Mishiro S., Miyamoto C., Furuichi Y., Hashimoto M., Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology 2001, 44:379-382.
130. Sugimoto Y., Kuzushita N., Takehara T., Kanto T., Tatsumi T., Miyagi T., Jinushi M., Ohkawa K., Horimoto M., Kasahara A., Hori M., Sasaki Y., Hayashi N. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J. Viral Hepat. 2002, 9:377-384.
131. Naito M., Matsui A., Inao M., Nagoshi S., Nagano M., Ito N., Egashira T., Hashimoto M., Mishiro S., Mochida S., Fujiwara K. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J. Gastroenterol. 2005, 40:381-388.
132. Apolinario A., Majano P.L., Alvarez-Perez E., Saez A., Lozano C., Vargas J., Garcia-Monzon C. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am. J. Gastroenterol. 2002, 97:2861-2870.
133. Wasmuth H.E., Werth A., Mueller T., Berg T., Dietrich C.G., Geier A., Gartung C., Lorenzen J., Matern S., Lammert F. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology 2004, 40:327-334.
134. An P., Nelson G.W., Wang L., Donfield S., Goedert J.J., Phair J., Vlahov D., Buchbinder S., Farrar W.L., Modi W., O'Brien S.J., Winkler C.A. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10002-10007.
135. O'Regan A.W., Nau G.J., Chupp G.L., Berman J.S., Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol. Today 2000, 21:475-478.
136. Mochida S., Hashimoto M., Matsui A., Naito M., Inao M., Nagoshi S., Nagano M., Egashira T., Mishiro S., Fujiwara K. Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem. Biophys. Res. Commun. 2004, 313:1079-1085.
137. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-S244.
138. Russmann S., Grattagliano I., Portincasa P., Palmieri V.O., Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 2006, 13:3351-3357.
139. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
140. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004, 140:346-355.
141. Page T., Connor J.D. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 1990, 22:379-383.
142. De Franceschi L., Fattovich G., Turrini F., Ayi K., Brugnara C., Manzato F., Noventa F., Stanzial A.M., Solero P., Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000, 31:997-1004.
143. Pastor-Anglada M., Cano-Soldado P., Molina-Arcas M., Lostao M.P., Larrayoz I., Martinez-Picado J., Casado F.J. Cell entry and export of nucleoside analogues. Virus Res. 2005, 107:151-164.
144. Govindarajan R., Endres C.J., Whittington D., LeCluyse E., Pastor-Anglada M., Tse C.M., Unadkat J.D. Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295:G570-G580.
145. Ibarra K.D., Pfeiffer J.K. Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J. Virol. 2009, 83:4538-4547.
146. Morello J., Cuenca L., Soriano V., Medrano J., Madejon A., Vispo E., Barreiro P., Labarga P., Jimenez-Nacher I., Rodriguez-Novoa S. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J. Infect. Dis. 2010, 202:1185-1191.
147. Fellay J., Thompson A.J., Ge D., Gumbs C.E., Urban T.J., Shianna K.V., Little L.D., Qiu P., Bertelsen A.H., Watson M., Warner A., Muir A.J., Brass C., Albrecht J., Sulkowski M., McHutchison J.G., Goldstein D.B. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010, 464:405-408.
148. Thompson A.J., Santoro R., Piazzolla V., Clark P.J., Naggie S., Tillmann H.L., Patel K., Muir A.J., Shianna K.V., Mottola L., Petruzzellis D., Romano M., Sogari F., Facciorusso D., Goldstein D.B., McHutchison J.G., Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011, 53:389-395.
149. Sumi S., Marinaki A.M., Arenas M., Fairbanks L., Shobowale-Bakre M., Rees D.C., Thein S.L., Ansari A., Sanderson J., De Abreu R.A., Simmonds H.A., Duley J.A. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 2002, 111:360-367.
150. Maeda T., Sumi S., Ueta A., Ohkubo Y., Ito T., Marinaki A.M., Kurono Y., Hasegawa S., Togari H. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol. Genet. Metab. 2005, 85:271-279.
151. Hitomi Y., Cirulli E.T., Fellay J., McHutchison J.G., Thompson A.J., Gumbs C.E., Shianna K.V., Urban T.J., Goldstein D.B. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011, 140:1314-1321.
152. Zdilar D., Franco-Bronson K., Buchler N., Locala J.A., Younossi Z.M. Hepatitis C, interferon alfa, and depression. Hepatology 2000, 31:1207-1211.
153. Pierucci-Lagha A., Covault J., Bonkovsky H.L., Feinn R., Abreu C., Sterling R.K., Fontana R.J., Kranzler H.R. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010, 51:137-148.
154. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
155. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., Arnold P.D., Richter M.A., Kennedy J.L., Murphy D.L., Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 2006, 78:815-826.
156. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol. Psychiatry 2009, 65:344-348.
157. Kraus M.R., Al-Taie O., Schafer A., Pfersdorff M., Lesch K.P., Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132:1279-1286.
158. Zhang Y., Burke C.W., Ryman K.D., Klimstra W.B. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J. Virol. 2007, 81:11246-11255.
159. Muller S., Moller P., Bick M.J., Wurr S., Becker S., Gunther S., Kummerer B.M. Inhibition of filovirus replication by the zinc finger antiviral protein. J. Virol. 2007, 81:2391-2400.
160. Bick M.J., Carroll J.W., Gao G., Goff S.P., Rice C.M., MacDonald M.R. Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J. Virol. 2003, 77:11555-11562.
161. Hayakawa S., Shiratori S., Yamato H., Kameyama T., Kitatsuji C., Kashigi F., Goto S., Kameoka S., Fujikura D., Yamada T., Mizutani T., Kazumata M., Sato M., Tanaka J., Asaka M., Ohba Y., Miyazaki T., Imamura M., Takaoka A. ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nat. Immunol. 2011, 12:37-44.
162. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 2007, 7:54-60.
163. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
164. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14:1095-1104.
165. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin. Neuropharmacol. 2010, 33:191-197.
166. Lotrich F.E., Loftis J.M., Ferrell R.E., Rabinovitz M., Hauser P. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J. Interferon Cytokine Res. 2010, [Epub ahead of print].
167. Harris M.A., Clark J., Ireland A., Lomax J., Ashburner M., Foulger R., Eilbeck K., Lewis S., Marshall B., Mungall C., Richter J., Rubin G.M., Blake J.A., Bult C., Dolan M., Drabkin H., Eppig J.T., Hill D.P., Ni L., Ringwald M., Balakrishnan R., Cherry J.M., Christie K.R., Costanzo M.C., Dwight S.S., Engel S., Fisk D.G., Hirschman J.E., Hong E.L., Nash R.S., Sethuraman A., Theesfeld C.L., Botstein D., Dolinski K., Feierbach B., Berardini T., Mundodi S., Rhee S.Y., Apweiler R., Barrell D., Camon E., Dimmer E., Lee V., Chisholm R., Gaudet P., Kibbe W., Kishore R., Schwarz E.M., Sternberg P., Gwinn M., Hannick L., Wortman J., Berriman M., Wood V., de la Cruz N., Tonellato P., Jaiswal P., Seigfried T., White R. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004, 32:D258-D261.